Torren Management’s Immunovant IMVT Stock Holding History

Torren Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21	Closed	-$534	–	1203
2025 Q4	$534	Buy	+21	New	+$468	﹤0.01%	1320

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Torren Management's IMVT Position: Q1 2026 in Review

Torren Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 21 shares — an estimated $534 sold.

Torren Management first reported a position in IMVT in Q4 2025 and held it in 1 quarter. The position peaked at $534 in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Torren Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Torren Management sold 21 Immunovant shares in Q1 2026, an estimated $534.
Torren Management first reported a position in Immunovant in Q4 2025 and held it in 1 quarter.
Torren Management's Immunovant position peaked at $534 in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.